Infection by bovine leukemia virus (BLV) is characterized by a long latency period, after which some individuals develop B-cell tumors. The behavior of BLV and related retroviruses during the latency period between initial infection and subsequent tumorigenesis is poorly understood. We used in situ hybridization to detect BLV transcripts in individual peripheral blood mononuclear cells from experimentally infected, asymptomatic sheep with latent infections. Viral RNA was not found in most peripheral blood cells that had been isolated as rapidly as possible from circulating blood, but it was present in rare cells. BLV RNA transcripts increased in a biphasic manner within a few hours after the blood cells were placed in culture.
Infection by bovine leukemia virus (BLV) is characterized by a long latency period, after which some individuals develop B-cell tumors. The behavior of BLV and related retroviruses during the latency period between initial infection and subsequent tumorigenesis is poorly understood. We used in situ hybridization to detect BLV transcripts in individual peripheral blood mononuclear cells from experimentally infected, asymptomatic sheep with latent infections. Viral RNA was not found in most peripheral blood cells that had been isolated as rapidly as possible from circulating blood, but it was present in rare cells. BLV RNA transcripts increased in a biphasic manner within a few hours after the blood cells were placed in culture. Exposure to fetal bovine serum was identified as the principal cause of this transcriptional activation, which occurred in fewer than 1 in 1,000 cells. Agents known to activate immune cells polyclonally caused a further increase in the number of cells containing BLV RNA within 8 h. In some cases, the numbers of viral transcripts within individual cells also increased. Thus, BLV is not detectably expressed in most resting lymphocytes circulating in the blood, but its transcription is activated by components of fetal bovine serum and can be augmented by molecules that mimic activation of immune cells. This activation, which might occur in lymphoid tissue during an immune response, may lead to the synthesis of viral regulatory proteins that are thought to initiate tumorigenesis through host cell genes.
Bovine leukemia virus (BLV), human T-cell leukemia virus types I and II (HTLV-I and HTLV-II, respectively), and human immunodeficiency virus (HIV) are all retroviruses that replicate in cells of the immune system. Infection by these viruses is followed by a long latency period, and a certain proportion of infected individuals then rapidly progress to terminal disease. Because these viruses integrate essentially at random into the host genome and do not contain cell-derived oncogenes, it is thought that the viral gene products themselves lead to development of disease. The genomes of BLV, HTLV, and HIV encode trans-acting factors that regulate viral transcription, but little is known about how viral transcripts that encode these regulatory proteins are initially induced. For HIV, recent evidence suggests that immune responses to unrelated antigens trigger virus replication and contribute to disease progression (reviewed in reference 15).
BLV, HTLV-I and HTLV-II are tumorigenic retroviruses that cause leukemia and lymphoma (reviewed in references 4 and 53) and are distinct from HIV, a lentivirus that causes fatal immunodeficiency and neuropathy of the central nervous system (reviewed in reference 15). BLV and HTLV-I share numerous features of infection and pathology. They also have similar genomic structures (43) and use common strategies for gene expression. The 3' ends of the genomes of HTLV and BLV contain the X sequences encoding a set of novel proteins (30, 39, 41, 45) that are necessary for efficient transcription from the viral promoter (7, 11, 40) and that determine the relative proportions of spliced and unspliced transcripts (12, 25, 27) . Aside from host range, a notable difference between the two viruses is that BLV infection is associated with malignancy of B cells, whereas HTLV affects T cells.
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Tumor cells contain at least part of one provirus, but the viral genome is not detectably expressed (16, 28) , which suggests that viral gene products are not necessary to maintain the transformed state. The X proteins encoded by the virus may set in motion a series of events leading to secondary genetic changes that result in malignant transformation (54) . It is important for two reasons to know where and under what conditions viral genes are expressed before tumor development begins. (i) Intermittent production and spread of the virus would favor transformation simply by increasing the population of cells at risk for such a genetic change. (ii) It is possible that the X-encoded proteins, tax and rex, could be produced from a subgenomic message without production of virions and that tax itself is responsible for changes in cells that could lead to uncontrolled growth (19, 26, 33) .
BLV-specific RNAs have not previously been detected in RNA extracted from populations of mononuclear cells newly purified from the blood of infected animals (20, 29) , but BLV transcripts were detected once these cells had been in short-term culture (20). However, low-level transcription in a few cells might escape detection unless individual cells were examined for viral transcripts. Virion proteins and viral particles have been detected in a few cells as early as 3 to 6 h after initiation of blood cell cultures but were most abundant after 24 to 48 h of culture (3, 14, 49) .
To examine infected cells during the latency period, when virus expression is likely to be important in disease development, we studied transcriptional activation of the BLV provirus in peripheral blood mononuclear cells (PBMCs) from infected but asymptomatic sheep that had no elevation of lymphocyte counts. We For plasma, 10 ml of blood was collected into 143 U of heparin (Sigma) and the tubes were centrifuged as described above. The supernatant was centrifuged at 500 x g for 3 min and then at 10,000 x g for 5 min to remove residual platelets and used immediately without storage.
Attachment of cells to glass slides. Slides were acid washed, treated with Denhardt solution, and acetylated as previously described (22) (24) . Hybridization was performed with minor modifications (9) . The Cells were deposited on slides within a circle 6 mm in diameter. To cover the samples, 22-mm2 siliconized cover slips were baked at 250°C for 4 h to ensure removal of RNases and scored diagonally and broken just before use. A 7.5-,ul volume of hybridization mixture was applied to each cytodot, which was covered with a siliconized half cover slip, and the edges were sealed with a generous portion of rubber cement. The slides were kept at 50°C on a slide warmer for 4 h (9). The rubber cement was carefully removed with forceps, and the slides with the cover slips were placed in a Coplin jar containing 50% formamide-2x SSC prewarmed to 50°C (24) . After 10 min, the cover slips were gently teased off and the slides were transferred to a second Coplin jar containing 50% formamide-2 x SSC at 50°C for an additional 10 min. After a brief rinse in 2x SSC, the slides were transferred to 2 x SSC containing 20 (52) , which contains an average of 3,000 full-length copies of viral RNA per cell (2), was used as a standard. Grains over FLK cells were reduced to a countable number by lowering the specific activity of the probe, and then grains formed after 4, 8, and 12 h of exposure to the emulsion were counted to determine the reduction in grains that was effected by reducing the exposure time. Finally, FLK cells that had been hybridized to a probe with the usual specific activity were exposed to the emulsion for 4 h and the numbers of grains counted were extrapolated to those that would have developed after 12 h of exposure.
RESULTS
BLV RNA-containing PBMCs found in freshly isolated cells from BLV-infected sheep. PBMCs were obtained from sheep experimentally infected with BLV. PBMCs freshly purified from the blood of these BLV-infected animals were analyzed by in situ hybridization with antisense RNA probes spanning the entire BLV genome and were found to contain BLV RNA. The frequency of viral-RNA-containing cells ranged from 1 in 2,000 cells to fewer than 1 in 500,000 cells, varying in each animal at different times after infection. Numbers within this range are characteristic of the latency period of virus infection in animals (manuscript submitted). This asymptomatic state lies between the initial establishment of infection and the later appearance of disease symptoms.
Representative samples of the rare cells expressing BLV RNA are illustrated in Fig. 1 . Silver grains indicate the presence of viral transcripts in a cell with lymphocyte morphology (Fig. 1A) amid freshly prepared PBMCs. Figure   1B shows how the level of viral RNA became elevated after the cells were cultured for 6 h. Cells with monocyte morphology occasionally also contained BLV RNA (Fig. 1C ), but cells with typical lymphocyte morphology were by far the most common BLV RNA-containing cells. Monocytes have not been described as hosts for BLV. Since there are no antibodies specific for sheep monocytes, our assignment of some of the relatively rare BLV-positive cells to the monocyte lineage was based on morphology alone.
Biphasic increase in BLV RNA in PBMCs from BLVinfected animals during short-term culture. BLV RNA has not been detected in PBMCs from infected animals until the cells have been cultured (21, 28) . This is at odds with our finding of BLV RNA in uncultured blood cells (Fig. 1) . We reasoned that the viral RNA we had detected in freshly prepared blood cells would not have been observed in previous studies if the number of BLV transcripts had been too low or if the BLV RNA had been present in too few cells to be detected. It was possible that we had identified rare BLV RNA-containing cells because of the single-cell sensitivity of in situ hybridization. Alternatively, the PBMCs might have begun to synthesize viral RNA during the interval between blood collection and fixation of cells on slides; this was up to 6 h. By the time cells were sampled for in situ hybridization, they had been kept at room temperature in medium containing 10% FBS for up to 3 h.
We first compared PBMCs that were rapidly isolated and fixed within 2 h of bleeding with those prepared during routine separation. The grains present over rapidly isolated cells were reduced in number and located primarily over the nuclei, suggesting that they represented newly synthesized RNA. To estimate the amount of RNA contained within infected cells in vivo, we measured BLV RNA in cells fixed at various intervals after their removal from the animals and extrapolated back to the time when the blood was drawn.
Experiments with four different animals showed that viral transcripts were either extremely rare or nonexistent in populations of infected PBMCs prepared as rapidly as possible after the bleeding of an animal (Fig. 2) . A constant number of cells representing those that most actively transcribed the viral genome was selected for analysis in each experiment, and transcriptional activity was averaged. BLV RNA appeared slowly during a lag that lasted for several hours, and then transcript levels increased rapidly. In early samples, grains were situated over the nuclei (as in Fig. 1A) , and in later samples they were also located over the cytoplasm (as in Fig. 1B) . Time points beyond 14 h were not included, since BLV RNA might have begun to appear in secondarily infected cells. Since the plots of grains per positive cell extrapolate essentially to zero at the time of bleeding, these data suggest that for animals in latency, BLV transcription does not take place in most infected cells while they circulate in the peripheral blood.
However, our analysis of transcription in single cells revealed that rare cells from rapidly processed samples of blood contained moderate amounts of BLV RNA. For example, among the PBMCs fixed by 2.3 h after the bleeding of animal 409 for the experiment shown in Fig. 2 plasma from BLV-infected animals (20) , and evidence for a transcriptional inhibitor has been presented (21) . Although the results of our blood storage experiments may be interpreted to mean that BLV expression is inhibited in blood, we were unable to block the appearance of BLV RNA in PBMCs by culturing these cells in autologous plasma. Freshly isolated PBMCs were rinsed free of platelets by centrifugation through FBS and then cultured in 100% autologous plasma for 6 to 24 h. Ih 17 different experiments, we found BLV RNA in these cells at levels equivalent to those found in individual cells under ordinary culture conditions, and most of the time, the number of cells that produced viral RNA was also equivalent.
Prompted by the report of a platelet-derived factor that activates BLV transcription, even in the presence of 100% plasma from BLV-infected animals (51), we repeated our experiments and omitted the rinse with FBS. Great care was taken during isolation of PBMCs to remove platelets gently without lysing them and to use platelet-cleared autologous plasma to wash residual platelets from the PBMC preparation. Despite these measures, some platelet lysis must have occurred because we observed some small clots upon microscopic inspection of stained slides. The results of experiments on cells from two animals are presented in Table 2 . The numbers of cells containing BLV RNA in samples cultured in 100% autologous plasma were reduced to 17 to 36% of the numbers found in samples cultured in medium with 10% FBS. However, the average amount of RNA per positive cell was not greatly affected by culturing the cells in plasma. Since cell viability was sometimes compromised by culture in plasma, we tried to separate the effects of culture conditions from those of an inhibitor of BLV transcription. The inhibitor of BLV transcription that has been found in (Table 2) . FBS is used in cultures as a source of growth factors and other regulators, so we investigated it as an activator in the culture medium.
We found that the number of cells containing BLV RNA when the cells were cultured with 1% FBS was less than the number observed in cultures with 10% FBS and was reduced even further in the absence of FBS (Fig. 3) Increased BLV RNA expression in PBMCs caused by immune cell activators. Treatment of PBMCs from BLV-infected animals with phytohemagglutinin (PHA), a T-cell mitogen, causes increased expression of BLV in culture (3, 6, 14, 49) . B-cell activators, such as LPS and PWM, reportedly do not stimulate synthesis of BLV virion proteins in PBMCs (6, 14) . These results are puzzling, because BLVinduced tumors are thought to arise from B cells (4) .
Since in situ hybridization allows examination of RNA in single cells, we tested immune cell activators for their early effects on BLV transcription before secondary events, such as cell survival and cell division, influenced the outcome. We treated PBMCs from infected sheep with LPS and found increased numbers of cells containing BLV RNA after 24 h of culture (data not shown). We then tested several T-and B-cell activators and mitogens for their effects on BLV expression in PBMCs obtained over a period of 8 months from four infected animals (Fig. 4) . We found BLV RNA in a higher proportion of the PBMCs if they were treated for 6 to 8 h in culture with any one of the activators-mitogens than if they were cultured with 10% FBS alone. Treatment In summary, the number of BLV transcripts present in a mixed population of mononuclear cells can be increased over that obtained by culture in 10% FBS when the cells are exposed to a variety of immune cell activators or mitogens.
DISCUSSION
Certain retroviruses that infect cells of the immune system become latent after the initial infection and may not cause disease for many years. For HIV, evidence is accumulating to suggest that immune activation of the T-cell host increases virus expression and in so doing may decrease the asymptomatic or latency period in vivo. HIV expression in cells in vitro is increased by certain T-cell activators (23, 34, 55) via increased HIV long terminal repeat (LTR) activity (48, 50) . Clinical studies suggest that immune activation by exposure to other infectious agents may accelerate the development of the acquired immunodeficiency syndrome in HIV-infected individuals (38) .
We report here a study of activation of BLV, a retrovirus that infects and induces malignancies of B lymphocytes. Activation of B cells to undergo proliferation and differentiation to antibody-producing cells can occur by distinct pathways that involve different regulatory signals (reviewed in references 5 and 10). We tested five different agents known to stimulate immune cells and found that all positively affect BLV transcription when added to a mixture of B cells, T cells, and monocytes isolated from BLV-infected animals. The mitogens could directly stimulate transcription within host cells of one or several lineages, or they could act through soluble mediators released locally within the mixed cultures. Factors in FBS also elicited BLV transcription in this cell population. Because these cells were examined for BLV transcripts within 8 h of treatment, and progression of B cells from quiescence into the Gl phase of the cell cycle probably requires 16 to 24 h (reviewed in reference 17), our data suggest that the cellular factors mediating transcription from the BLV LTR are positively regulated at a very early step in B-cell activation.
If BLV is transcribed only when infected cells are activated, as our results suggest, it is not surprising that BLV transcription in PBMCs would be extremely rare in vivo. (19, 26, 33) could occur in the absence of further progression of the viral life cycle. The increase in BLV RNA that we found in blood cells placed in culture appeared to be biphasic, with a slow rate of RNA synthesis followed by rapid enhancement of transcription. Although the viral,transactivator proteins are necessary for efficient transcription from the viral promoter (7, 40) , transcription of viral genes must begin in the absence of these proteins, since synthesis of the transactivator protein itself requires transcription of the viral genome. Cellular transcription factors induced by activation of lymphocytes may initiate a low level of transcription from viral promoters and so lead to synthesis of small amounts of the viral transactivator, which could then amplify transcription. The biphasic increase in BLV RNA that we observed may reflect such a sequence of events.
Transcriptional regulatory elements are found in the proviral LTR. DNase I protection assays suggest that the HTLV-I LTR is recognized not by viral proteins but by multiple host cell factors (1, 37) . Interestingly, the BLV LTR sequence (8, 42) contains six bases, CTTTCC, at positions -87 to -82 that are part of the kappa light-chain enhancer (46) and are located in exactly the same position relative to the cap site as in the HIV LTR. Activation of T cells greatly increases factor binding to this kappa light-chain enhancer sequence with a concomitant increase in HIV expression (36) .
NF-KB is a nuclear protein that binds the kappa lightchain enhancer (46) and is activated posttranslationally in pre-B cells treated with LPS or phorbol ester (47) . An NF-KB-like factor responsive to B-cell activation may mediate initial, low-level BLV transcription. Higher levels of transcription could then be induced once the viral transactivator has been synthesized. The HTLV-I transactivator protein has recently been shown to induce factor binding to a kappa light-chainlike enhancer located upstream of the interleukin 2 receptor gene (32) . Thus, cellular factors, such as NF-KB, may be involved not only as the initial activators of viral transcription but also as targets whose activities are modified by the viral transactivator protein. Although the mechanisms are not known, it seems likely that expression of a latent immune system retrovirus, whether it be BLV, HTLV, or HIV, depends on participation of host cell factors induced or modified during an immune response. If so, immune responses to unrelated antigens could facilitate spread of the virus and shorten the asymptomatic or latency stage of the disease.
